Alissa Keegan

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

Alissa Keegan, Biagio Ricciuti, Padric M. Garden et al. · Journal for ImmunoTherapy of Cancer · 2020 · 150 citations · Full text

CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

Sumanta K. Pal, Ben Tran, John B.A.G. Haanen et al. · Cancer Discovery · 2024 · 124 citations · Full text

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study

Swaminathan P. Iyer, R. Alejandro Sica, P. Joy Ho et al. · The Lancet Oncology · 2024 · 56 citations · Full text

Dose-escalation Study, Cell Therapy, Novel Therapy +13

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

J. Randolph Hecht, Steven S. Raman, Arlene Chan et al. · ESMO Open · 2023 · 32 citations · Full text

Impact of clinical sample handling and processing on ultra-low level measurements of plasma cytokines

Limor Cohen, Alissa Keegan, Stacy E.F. Melanson et al. · Clinical Biochemistry · 2019 · 30 citations

Inflammation, Cytokine, Allergy +11